A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2019
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics; Registrational
- Sponsors Takeda
- 06 Feb 2019 Status changed from active, no longer recruiting to completed.
- 01 Aug 2018 Planned End Date changed from 28 Nov 2018 to 28 Jan 2019.
- 01 Aug 2018 Planned primary completion date changed from 16 Jun 2018 to 28 Jan 2019.